Stevanato Group S.p.A. $STVN Position Lessened by UBS Group AG

UBS Group AG trimmed its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 47.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 158,078 shares of the company’s stock after selling 144,673 shares during the period. UBS Group AG’s holdings in Stevanato Group were worth $3,181,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. State of Wyoming raised its holdings in shares of Stevanato Group by 39,216.7% during the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after acquiring an additional 2,353 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Stevanato Group during the third quarter worth $68,000. Van Berkom & Associates Inc. raised its holdings in shares of Stevanato Group by 50.6% during the third quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock worth $93,000 after acquiring an additional 1,215 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Stevanato Group by 1,268.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after acquiring an additional 4,250 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Stevanato Group by 391.4% during the fourth quarter. Farther Finance Advisors LLC now owns 8,324 shares of the company’s stock worth $167,000 after acquiring an additional 6,630 shares in the last quarter.

Stevanato Group Price Performance

NYSE STVN opened at €18.12 on Monday. Stevanato Group S.p.A. has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The stock’s 50-day moving average is €15.68 and its two-hundred day moving average is €18.13. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.63 and a quick ratio of 1.11. The firm has a market cap of $5.49 billion, a P/E ratio of 30.72, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75.

Stevanato Group (NYSE:STVN) last posted its earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The company had revenue of €273.57 million for the quarter. During the same quarter in the prior year, the business posted $0.10 EPS. Stevanato Group’s quarterly revenue was up 6.6% on a year-over-year basis. On average, analysts anticipate that Stevanato Group S.p.A. will post 0.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STVN has been the subject of several recent research reports. Weiss Ratings lowered Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. Citigroup cut their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 5th. KeyCorp cut their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a report on Tuesday, February 10th. Finally, Morgan Stanley cut their target price on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a report on Friday, March 6th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Stevanato Group has an average rating of “Hold”.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.